Immutep Limited (ASX:IMM) completes $29.6m placement to expand clinical development

Latest Company News - Finance News Network

English - November 19, 2020 00:00 - 56 seconds - 1000 KB
Business News News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: AFT Pharmaceuticals (ASX:AFP) growth continues despite Covid-19

Next Episode: Flexigroup (ASX:FXL) rebrands as humm to tap BNPL fertility market

19 Nov 2020 - Immutep Limited (ASX:IMM) is advancing clinical development for its lead product candidate eftilagimod alpha through the expansion of its ongoing TACTI-002 study and a new Phase II trial.